Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome

Bone Marrow Transplant. 2020 Nov;55(11):2204-2206. doi: 10.1038/s41409-020-0925-2. Epub 2020 May 6.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Hydrazines
  • Leukemia, Myeloid, Acute* / therapy
  • Myelodysplastic Syndromes* / therapy
  • Transplantation Conditioning
  • Triazoles

Substances

  • Hydrazines
  • Triazoles
  • selinexor